[A case of Melkersson-Rosenthal syndrome. Nosologic remarks].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Baran.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Onychomatricoma is a rare tumour of the nail matrix with peculiar clinical and histological features and electron microscopic findings. We report on 5 cases with appearances which were misleading. Three presented as longitudinal melanonychia, a previously unreported observation. One case had the appearance of a cutaneous horn. In 3 of the 5 cases the tumour was associated with an onychomycosis and this may thus have been a predisposing factor in the secondary fungal infestation. Onychomatricoma appears as a multi-faceted tumour which can be mimicked by longitudinal melanonychia and/or onychomycosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Diagnosing nail dystrophies and understanding their pathogenesis is best accomplished if the origin of the disorder is first established. Exogenous. In this group, the nail plate is altered by exogenous factors and is the site of primary involvement: periungual tissues may be affected secondarily. Endogenous. In this group, the nail plate is altered secondarily by changes occurring in the matrix, proximal nail fold, nail bed, hyponychium or underlying bony phalanx.
After having reviewed the conditions of use of an antimycotic-corticoid combination, the authors are reporting their clinical results on 183 patients of a new drug combining econazole and triamcinolon. This clinical trial demonstrates that the own activity of each component of the combination is entirely maintained, and that the new combination shows an original interest in the treatment of all inflammatory dermatomycoses, as well as inflammatory supra-infected dermatoses.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.